Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer

被引：0
|
作者：
Li, Y. [1 ]
Chen, Z. [2 ]
Wu, L. [1 ]
Tao, W. [1 ]
机构：
[1] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Tumor Mutation Score; Tumor Mutation Burden; PD-L1;
D O I：
10.1016/j.jtho.2019.08.1545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-40
引用
收藏
页码：S724 / S724
页数：1
相关论文
共 50 条
  • [1] Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer
    Li, Yuan
    Chen, Zuhua
    Tao, Weiping
    Sun, Nan
    He, Jie
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (08) : 2367 - 2378
  • [2] Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer
    Yuan Li
    Zuhua Chen
    Weiping Tao
    Nan Sun
    Jie He
    Cancer Immunology, Immunotherapy, 2021, 70 : 2367 - 2378
  • [3] Tumor mutation burden as emerging biomarker in non-small cell lung cancer and beyond
    Fischer, Rieke N.
    Wolf, Juergen
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S770 - S773
  • [4] Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer
    Sharpnack, Michael F.
    Cho, Ju Hwan
    Johnson, Travis S.
    Otterson, Gregory A.
    Shields, Peter G.
    Huang, Kun
    Carbone, David P.
    He, Kai
    LUNG CANCER, 2020, 146 : 36 - 41
  • [5] Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
    Cai, Liangliang
    Bai, Hua
    Duan, Jianchun
    Wang, Zhijie
    Gao, Shugeng
    Wang, Di
    Wang, Shuhang
    Jiang, Jun
    Han, Jiefei
    Tian, Yanhua
    Zhang, Xue
    Ye, Hao
    Li, Minghui
    Huang, Bingding
    He, Jie
    Wang, Jie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] Genetic and Epigenetic Alterations are Associated with Tumor Mutation Burden in Non-Small Cell Lung Cancer
    Cai, L.
    Bai, H.
    Wang, Z.
    Wang, S.
    Duan, J.
    Gao, S.
    He, J.
    Wang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S377 - S377
  • [7] Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer
    Lam, Vincent K.
    Zhang, Jianjun
    JOURNAL OF THORACIC DISEASE, 2019, 11 (06) : 2208 - 2211
  • [8] Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy
    Nie, Wei
    Xu, Mi-Die
    Gan, Lu
    Zhang, Yi
    Qian, Jie
    Gu, Kai
    Zhang, Xue-Yan
    Wang, Hui-Min
    Yan, Bo
    Gu, Ping
    Zhang, Bo
    Wang, Shu-Yuan
    Hu, Fang
    Li, Chang-Hui
    Zhong, Hua
    Han, Bao-Hui
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (06) : 189 - 195
  • [9] Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden
    Muto, Satoshi
    Ozaki, Yuki
    Yamaguchi, Hikaru
    Mine, Hayato
    Takagi, Hironori
    Watanabe, Masayuki
    Inoue, Takuya
    Yamaura, Takumi
    Fukuhara, Mitsuro
    Okabe, Naoyuki
    Matsumura, Yuki
    Hasegawa, Takeo
    Osugi, Jun
    Hoshino, Mika
    Higuchi, Mitsunori
    Shio, Yutaka
    Nanamiya, Hideaki
    Imai, Jun-Ichi
    Isogai, Takao
    Watanabe, Shinya
    Suzuki, Hiroyuki
    ONCOLOGY LETTERS, 2021, 21 (03)
  • [10] High Tumor Mutation Burden in Small-Cell Lung Cancer May Predict Improved Immunotherapy Response
    不详
    ONCOLOGY-NEW YORK, 2017, 31 (11): : 836 - +
12345